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ABSTRACT 
Objective: To determine the effectiveness of a patient-initiated DMARD self-monitoring 
service for people with rheumatoid (RA) or psoriatic arthritis (PsA) on methotrexate. 
Methods: A two-arm, single centre, randomised controlled trial assessing superiority in 
relation to healthcare utilisation, clinical and psychosocial outcomes. Participants were 100 
adults with either RA or PsA on a stable dose of methotrexate, randomly assigned to usual 
care or the patient-initiated service. Intervention participants were trained how to 
understand and interpret their blood tests and use this information to initiate care from 
their clinical nurse specialist (CNS). The primary outcome was the number of outpatient 
visits to the CNS during the trial period. Differences between groups were analysed using 
Poisson regression models. Secondary outcomes were collected at baseline and after the 3rd 
and 6th blood tests. Disease activity was measured using either the DAS28 or PsARC, pain 
and fatigue using a visual numeric scale and the HAQII, HADS and SF12 were completed to 
assess disability, mood and quality of life, respectively. Differences between groups over 
time on secondary outcomes were analysed using multi-level models.  
Results: The patient-initiated DMARD self-monitoring service was associated with 54.55% 
fewer visits to the CNS (p<0.0001), 6.80% fewer visits to the rheumatologist (p=0.23) and 
38.80% fewer visits to the GP (p=0.07), compared with control participants. There was no 
association between trial arm and any of the clinical or psychosocial outcomes.  
Conclusions: The results suggest that a patient-initiated service that incorporates patients 
self-monitoring DMARD therapy can lead to significant reductions in healthcare utilisation, 
whilst maintaining clinical and psychosocial well-being. 
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INTRODUCTION 
Rheumatoid (RA) and psoriatic arthritis (PsA) are chronic inflammatory conditions. Both 
primarily affect the joints, and have a wide clinical spectrum from mild joint symptoms to 
severe inflammation and damage. In some cases drug-induced sustained remission is 
possible.[1-2] The prevalence of PsA ranges between 1 and 420 cases per 100,000, 
depending on country,[3] whilst the prevalence of RA in Western Europe is 0.44%.[4] 
 
Rheumatology services have seen increasing numbers of patients with arthritis over the last 
30 years. This in part reflects the increasing complexity of drug treatments and more 
intensive monitoring regimes. As a result the number of follow-up cases in rheumatologist 
outpatients service has increased.[5] The introduction of nurse-led care has reduced some 
of this demand and has been found to be equally as effective, as well as cost-effective, in 
managing disease activity as rheumatologist-led clinics.[6-7] Despite this, the monitoring 
requirements remain burdensome for both the health system and patients, with increased 
waiting times for new referrals and the lack of availability of urgent appointments for 
established patients. Data from the National Audit Office[8] in the UK indicated that 66% of 
healthcare trusts were unable to offer RA patients a timely follow-up appointment. Even 
when these appointments do occur, 30% lead to no investigation or other actions, 35% are 
seen to be problem free by rheumatologists and 42% completely unnecessary.[9] As a 
result, the focus is now on reducing unnecessary outpatient and follow-up appointments 
altogether, rather than simply redirecting care.[10] 
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One way in which this may be achieved is through the use of patient-initiated services, in 
which patients are encouraged to take an active role in initiating their own care. This 
approach is supported by over 40% of patients with arthritis, who feel they should be able 
to decide how frequently they need a check-up[11] and want to take responsibility for 
organizing their own DMARD monitoring appointments.[12] Whilst the traditional 
rheumatology system assumes that patients need to be seen on a regular basis as decided 
by clinicians, patient-initiated services allow the patient to access rheumatology services 
much like they do in primary care. A recent systematic review[13] concluded that UK policy 
is eager for evidence-based patient-initiated services to be implemented and evaluated 
qualitatively and quantitatively so that the time of both patients and healthcare 
professionals is not wasted and costs can be minimised. The trials reported within this 
systematic review[14-17] and subsequent evaluations[18-23] have found that patients with 
arthritis are able to appropriately self-refer, and that despite reducing hospital 
appointments, the clinical or psychological well-being of patients is not compromised.  
 
To date this model of care has however, focused on the implementation of patient-initiated 
clinics in the context of rheumatologist-led services, as opposed to the nurse-led clinics 
where much of DMARD monitoring takes place.[24] In addition, previous patient-initiated 
services have used symptoms as triggers for contact[14-23] but, in order for this model of 
care to be implemented in a nurse-led monitoring clinic, patients would need to monitor 
their laboratory results, as well as their symptoms and any side effects, and use this 
information together to initiate care from their CNS.  
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The aim of this study is therefore to determine whether a patient-initiated DMARD self-
monitoring follow-up service, in which patients monitor their symptoms and blood test 
results and used this information to initiate care from their CNS, reduces use of nurse-led 
rheumatology clinics, in comparison to treatment as usual and that any reduction is not 
offset by use of other healthcare services. 
  
METHODS 
Trial design 
This was a two-arm, single centre, randomised controlled trial (RCT) with balanced 
randomisation (1:1), and conducted in the UK. 
 
Participants 
Participants were recruited from the Department of Rheumatology at University College 
Hospital, UK and were approached by postal invitation 2 weeks prior to their attendance at 
the nurse-led DMARD monitoring clinic. Inclusion criteria were those with diagnosed RA[25] 
or PsA[26] whose treatment was classified as stable. This was defined as treatment with 
methotrexate for at least 6 months, plus a further 3 months if the patient were receiving 
one of two self-injecting anti-TNF agents; adalimumab or etanercept. Exclusion criteria were 
patients with a significant co-morbidity (i.e. their predominant treatment was for another 
illness), those for whom blood tests and monitoring was undertaken by their GP and 
patients prescribed infliximab. Ethical approval was obtained (Camden and Islington 
Community Local Research Ethics Committee Ref. 09/H0722/91) and all participants 
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provided written informed consent and were enrolled into the study by the research 
assistant. 
 
Intervention 
All participants randomised to the intervention group took part in a group based training 
session to provide them with the knowledge, skills and resources required to self-monitor 
and initiate care. This one-off 2 hour training session was delivered by a rheumatologist and 
a Health Psychologist, with a group of between 2-6 patients. Participants were trained how 
to identify normal or “safe” ranges of blood levels, side effects and symptoms, decide if any 
action was necessary, and how to initiate care from their CNS. Participants were guided 
through example blood test scenarios and given practice materials to be completed during 
the session. The results of these tasks were then reviewed during group discussions led by 
the rheumatologist.  
 
Participants interpreted markers of inflammation (CRP and ESR), plus haemoglobin, white 
blood cell count, liver function tests (ALP and ALT), platelets and neutrophils. Participants 
continued to receive routine care from their rheumatologist, defined as outpatient 
appointments every 6 months; had access to the emergency nurse helpline if necessary and 
continued with routine blood monitoring every 4-6 weeks depending on their dose of 
methotrexate.  
 
Following each blood test, participants were sent a copy of their results either via email or 
post, depending on the patient’s preference. Included were the patient’s previous blood 
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test results, to enable calculation of change scores by the participant. Criteria for a 
significant change or out-of-range blood test were developed and agreed by the clinical 
team and shared with the patient (Table 1). 
 
Table 1. Normative ranges by blood test 
Test  Normal Range  Definition of significant change  
Haemoglobin  12.0 - 17.0  Fall of more than 1.0  
WBC  3.0 - 10.0  Two readings in a row each with a fall of more than 1.0  
Neutrophils  2.0 - 7.5  A fall of more than 2  
Platelets  150 - 400  Two readings in a row with falls of more than 50  
ALP  40 - 129  A result which doubles from the previous blood test or 
rises 258  
ALT  10 - 50  A results which doubles from the previous blood test or 
rises above 100  
ESR  0 - 20  A rise of more than 20 from the previous blood test 
results  
CRP  0 - 5  A rise of more than 20 from the previous blood test 
results  
WBC - White Blood Count; ALP - Alkaline Phosphatase; ALT - Alanine Transaminase; ESR - Erythrocyte 
Sedimentation Rate; CRP - C-Reactive Protein 
 
Participants also recorded, using a 17-item checklist developed by the authors, the side 
effects and symptoms they had experienced since their last blood test, indicating if they 
were any new or continuing symptoms. For continuing symptoms participants indicated if 
the symptom had become worse, better or remained the same since their last blood test. 
The criteria for seeking a telephone consultation with the CNS are outlined in Figure 1.  
 
Control group 
Participants in the control group received standard care; this typically consisted of a blood 
test every 4-6 weeks and optimally outpatient appointments with their CNS every 3 months 
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and rheumatologist every 6 months. Advice was also freely available via the emergency 
nurse helpline when requested.  
 
Participant safety 
The blood tests of all intervention participants were reviewed both by the researcher and 
CNS independently of the patient. Any serious concerns about the health and care of these 
patients were acted upon immediately. If the participant had any concerns about any aspect 
of their healthcare they were able to contact their clinical team by email or telephone. This 
included the CNS helpline or rheumatologist, where patients were responded to within 24-
48 hours. 
 
Outcomes 
The primary outcome was visits to the nurse-led rheumatology clinic, and secondary 
outcomes visits to the rheumatologist and GP, disease activity, time between blood tests, 
pain, fatigue, disability, quality of life and mood. All patient reported outcomes measures 
were assessed at baseline, and after the 3rd and 6th blood tests. 
 
Healthcare utilisation 
Healthcare utilisation included outpatient visits to the CNS and rheumatologist, arthritis-
related GP visits and telephone consultations with the CNS. Data on outpatient visits were 
taken from electronic patients records at the end of the trial period. Data on GP visits were 
provided by participants at each of the assessment points. A cumulative frequency of visits 
across the trial period was calculated for each participant, for each healthcare professional. 
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Disease activity 
Disease activity was measured using the DAS28 (ESR)[27] for patients with RA and the 
PsARC[28] for patients with PsA. A response to treatment score was calculated using either 
the EULAR response criteria[29] or the PsARC[28]. The EULAR response criteria of 
‘moderate’ and ‘good’ were recoded as a response; and ‘none’ as no response in order to 
correspond with the PsARC.  
 
Pain and fatigue 
Pain and fatigue were measured using two separate visual numeric scales which were 
displayed as histograms.[30] The histograms become larger in size and darker in colour as 
the severity of the pain or fatigue increases (from left to right). Scores ranged from 0 to 10, 
with the higher scores indicating greater pain or fatigue experienced in the past 2 weeks.  
 
Functional disability 
The Health Assessment Question-II (HAQ-II)[31] is a 10-item scale with responses from 
‘without any difficulty’ (1) to ‘unable to do’ (4). The individual Likert scales range from 0-3, 
these items are then averaged, and hence the overall score for the scale is also 0-3 Higher 
scores represent greater levels of functional disability. The HAQ-II possess satisfactory 
reliability and correlates well with the full version of the HAQ,[32] quality of life and clinical 
outcomes.[33] 
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Mood 
The Hospital Anxiety & Depression Scale (HADS)[34] is a 14-item self-screening 
questionnaire for depression and anxiety. The two 7-item subscales, measure how a person 
has been feeling in the past week. The scale scores range from 0-21, with higher scores 
indicating greater levels of anxious or depressed mood. The scales possess excellent internal 
consistency[35] and high test-retest reliability.[36]  
 
Quality of life 
The SF-12v1[37] measures quality of life across two component summary scales - the 
Physical (SF-12v1® PCS) and Mental Component Summary (SF-12v1® MCS). Total scores 
range from 0-100 with higher scores representing better quality of life. The scale is 
responsive to change and has good test retest reliability.[38]  
 
Sample size 
An a priori power calculation was conducted using G-Power 3.1.[39] An initial power 
calculation was performed using data from a previous trial of patient-initiated services,[15] 
however, to make group comparisons on the primary outcome – outpatient visits to the 
nurse specialist, a total sample size of 10 participants would be required at 80% power 
(α=0.05), with an effect size of 2.45. The magnitude of the effect size and hence sample size 
were deemed inappropriate for a trial of effectiveness and, therefore, a generic sample size 
calculation was conducted a total sample size of 134 participants was required at 80% 
power (α=0.05), with a medium effect size of 0.50. 
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Randomisation 
Participants were randomised with a randomization plan generator,[40] using randomly 
permuted blocks of 10 participants, by the research assistant. As with interventions of this 
type group allocation was not concealed. No stratification took place. 
 
Blinding 
Due to the nature of the intervention blinding of participants and treating healthcare 
professionals was not possible. The analysis was not performed blind to group allocation.  
 
Statistical methods 
The analysis followed a per-protocol and intention-to-treat approach for the primary 
outcomes. In order to test the robustness of the findings in relation to the secondary 
outcomes sensitivity analyses were performed for complete (i.e. all three administrations of 
the questionnaire) and available case cohorts. Univariate Poisson regressions were 
performed to explore if trial arm (independent variable) was associated with healthcare 
utilisation (dependant variable). Multi-level modelling was used to explore changes over 
time and differences between groups on pain, fatigue, functional disability, mood and 
quality of life. Interaction effects between group and time on disease activity were analysed 
using a mixed between-within participants ANOVA for the DAS28 and the individual 
subscales of the PsARC. An independent samples t-test was used to explore differences 
between trial arms on the time between laboratory tests.  
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Across the entire dataset there were 3.65% missing data, which was missing completely at 
random (p = 0.53). MLM allows for missing data, all other analyses were undertaken on the 
multiple imputed datasets. Constraints and rounding were used to ensure that the imputed 
scale level data was meaningful and corresponded to possible values. Ten scale-level 
imputation iterations were used to eliminate bias.[41] Analyses were performed on each of 
these 10 datasets and then pooled. 
RESULTS 
Of the 301 patients assessed for eligibility, 25% (n = 74) did not meet the eligibility criteria 
therefore, 227 patients were approached to take part (Figure 1). Of these 63% (n = 128) 
consented and were randomised. Of those who did not consent the most frequently 
reported reasons for refusal were ‘too busy to participate’ (n = 58, 59.09%) and a 
‘preference to see their CNS face-to-face’ (n = 31, 31.82%). Of the 128 patients who were 
randomised, 16 (12.50%) failed to complete a baseline questionnaire, 9 (7.03%) failed to 
attend the intervention training session and 3 (2.34%) participants were no longer eligible to 
take part in the trial. A total of 100 participants, therefore, received their allocated group, 
52 (85.54%) in the intervention arm and 48 (73.85%) in the control arm (Figure 2). Analyses 
were performed on an ITT basis (n = 100) and repeated in complete cases only (n = 79), but 
with no differences; hence results for the whole sample (n = 100) are presented.  
 
Sample characteristics 
Participant characteristics at baseline can be found in Table 2.  
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Table 2 Sample characteristics 
 
Intervention  
(n=52) 
Control  
(n=49) 
Age, mean(SD) 54.83(11.22)  58.75(12.22)  
Female, n(%) 24(46.15) 31(64.58) 
Living status, n(%) 
Married or living with partner 
Living alone 
Living with friends or family 
  
37(71.15) 
8(15.38) 
7(13.46) 
  
33(68.75) 
10(20.83) 
5(10.42) 
Ethnicity,† n(%) 
White 
Indian 
Other 
Black-African 
Black-Caribbean 
Chinese 
 
46(88.46) 
2(3.85) 
3(5.77) 
0(0.00) 
1(1.92) 
0(0.00) 
 
43(89.58) 
2(4.17) 
1(2.08) 
1(2.08) 
0(0.00) 
1(2.08) 
Disease type, n(%) 
Rheumatoid arthritis 
Psoriatic arthritis 
  
33(63.46) 
19(36.54) 
  
38(79.17) 
10(20.83) 
Disease duration in years, median(range) 8(1-40) 6(1-54) 
No. of years on methotrexate, median(range) 4(1-20) 3.85(1-13) 
Dose of methotrexate, median (range) 15(5-22.5) 15(5-25) 
No. of medications, median(range)ǂ 4(1-10) 5(2-11) 
Co-morbidities, n(%) 
Hypertension 
Hypercholesterolemia 
Hypothyroidism 
Osteoporosis 
Diabetes 
Respiratory 
  
9(17.31) 
8(15.38) 
2(3.85) 
2(3.85) 
2(3.85) 
1(1.92) 
  
5(10.42) 
5(10.42) 
4(8.33) 
4(8.33) 
2(4.17) 
2(4.17) 
 
Primary outcome 
The intervention group initiated 54.6% fewer appointments with their CNS compared to 
control participants. Group was a significant predictor of outpatient visits to the CNS (Table 
3). The intervention group attended 6.8% fewer reviews with their rheumatologist over the 
trial period compared to the control group participants (Table 3). Poisson regression 
indicated that group was not a significantly associated with visits to the rheumatologist 
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(Table 3). The intervention group initiated 38.8% fewer arthritis-related GP appointments 
than control group participants; this difference was also not statistically significant.  
 
Table 3. Total number of face-to-face arthritis-related healthcare visits by trial arm for 
whole sample  
Healthcare 
profession 
Total  
n=100 
Intervention  
n=52 
Control  
n=48 
Difference 
between 
groups, 
AD(%) 
(C – I) Statistic 
CNS 96 30 66 36(54.5%) Exp(β) = 2.37 
χ2(1, n = 100) = 15.48  
p < 0.0001 
Rheumatologist 199 96 103 7(6.80%) Exp(β)=1.04 
χ2(1, n=100) = 1.16  
p = 0.23 
GP 76 29 47 18(38.30%) Exp(β) = 1.78 
χ2(1, n = 100) = 3.64 
p = 0.07 
AD - actual difference; χ2 -  chi-squared test; Exp(β) – incident rate ratio 
 
In the intervention group a total of 231 telephone consultations took place (mean per 
participant = 4.43, SD = 1.43). All intervention participants required at least one telephone 
consultation during the trial period, 15 (29.23%) participants required a telephone 
consultation at each of their six blood tests. For every seven telephone consultations one 
outpatient appointment was requested. Of these 231 telephone consultations, 74.7% were 
initiated appropriately by the patient in response to their results, and 25.3% were initiated 
by the CNS when abnormal blood results were detected, but not acted on by the patient. 
Two participants in the intervention were removed from the trial for safety reasons as they 
were deemed unable to self-monitor their laboratory results safely. Patients ability to safely 
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initiate care improved significantly over the trial period (F1,278 = 9.24, p = 0.003), from 65.4% 
of all decisions at blood test 1 to 89.1% at blood test 6.  
 
Secondary outcomes 
There was also no significant association between trial arm and disease response to 
treatment χ2(1, n = 100) = 0.35, p = 0.77, φ = -0.03.  
 
 
There were no statistically significant interaction effects between group and time on any of 
the laboratory results, see the online supplementary material Table S1.  
 
Intervention participants attended for their laboratory tests more frequently (M = 39.35 
days, SD = 9.12 days) than control group participants (M = 47.88 days, SD = 13.50 days; t 
(79.84) = 3.63, p = 0.001, η2 = 0.12). There were no statistically significant interaction effects 
on levels of disability, pain, fatigue or any of the psychosocial outcomes. (Table 4).  
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Table 4. Descriptive statistics adjusted mean(SD) and MLM analysis for pain, fatigue and functional disability (n=100) 
Variable Trial arm Baseline First f/u Final f/u Group Time Time*Group 
Fatigue Intervention 4.20(2.74) 4.53(2.87) 4.30(2.90) 
F1,97.20 = 0.11,  
p = 0.74 
F2,115.21 = 0.68,   
p = 0.51  
F2,115.21 = 0.45,  
p = 0.64  Control 4.35(2.70) 4.50(2.79) 4.69 (2.93) 
Effect size(99% CI) 0.01(-0.97, 0.99) 0.13(-0.90, 1.16) 
Pain Intervention 3.64(2.46) 3.56(2.70) 3.68(2.60) 
F1,95.62 = 0.24,  
p = 0.63  
F2,159.60 = 0.65,   
p = 0.53 
F2,159.60 = 0.84,  
p = 0.43 Control 3.50(2.43) 4.12(2.56) 3.86(2.70) 
Effect size(99% CI) 0.21(-0.67, 1.09) 0.07(-0.90, 1.03) 
Functional 
Disability 
Intervention 0.59(0.62) 0.55(0.64) 0.56(0.63) 
F1,95.18 = 1.12,  
p = 0.29 
F2,110.04 = 0.51,   
p = 0.60 
F2,110.04 = 2.01,  
p = 0.14 Control 0.64(0.62) 0.74(0.63) 0.70(0.64) 
Effect size(99% CI) 0.29(0.07, 0.51) 0.22(0.00, 0.45) 
Anxiety Intervention 5.73(4.22) 5.84(4.39) 5.06(4.38) 
F1,98.61 = 2.51,  
p = 0.12 
F1,107.47 = 1.28,   
p = 0.28 
F1,107.47 = 1.85,  
p = 0.16 Control  6.46(4.21) 7.01(4.34) 6.97(4.45) 
Effect size(99% CI) 0.26(-1.25,1.78) 0.43(-1.14, 2.00) 
Depression Intervention 4.63(3.33) 4.44(3.49) 4.11(3.46) 
F1,97.24 = 0.001, 
p = 0.98 
F1,132.01 = 0.22,  
p = 0.81 
F1,132.01 = 1.20,  
p = 0.31 Control  4.25(3.33) 4.50(3.42) 4.51(3.52) 
Effect size(99% CI) 0.02(-1.18, 1.21) 0.11(-1.14, 1.36) 
SF-12v1® MCS Intervention 30.15(7.48) 29.18(7.72) 30.99(7.80) 
F1,89.00 = 0.02,  
p = 0.89 
F2,84.85 = 1.49,  
p = 0.23 
F2,84.85 = 1.48,  
p = 0.23 Control  30.91(8.36) 29.60(7.62) 29.26(8.22) 
Effect size(99% CI) 0.05(-2.62, 2.73) 0.21(-2.55, 2.97) 
SF-12v1® PCS Intervention 46.82(11.41) 46.34(11.83) 45.26(11.71) 
F1,90.22 = 0.28,  
p = 0.60 
F2,99.16 = 0.07,  
p = 0.94 
F2,99.16 = 1.02,  
p = 0.36 Control  44.30(12.57) 45.22(11.73) 45.59(12.38) 
Effect size(99% CI) 0.09(-3.99, 4.18) 0.03(-4.20, 4.26) 
SD – Standard Deviation; MLM – Multi-Level Modelling; CI – Confidence Interval; f/u – follow-up; MCS – Mental Component Score; PCS – Physical Component Score
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DISCUSSION 
This is the first evaluation of a patient-initiated service that has integrated patients self-
monitoring their DMARD therapy and interpreting of their own laboratory results, and using 
this information along with their symptoms to seek care from rheumatology services. The 
primary findings of this RCT indicated that this novel model of care led to significant 
reductions in outpatient visits to the CNS and a reduction in visits to the GP, whilst 
maintaining the regularity with which patients saw their rheumatologist. Despite this 
reduction in attendance in primary and secondary care services, this new service was not 
inferior to standard practices in regards to disease activity, pain, fatigue, quality of life or 
mood. These results suggest that this model of care could be implemented without 
compromising the clinical or psychological well-being of patients with either RA or PsA on 
methotrexate, and are consistent with previous studies of patient-initiated services in the 
UK[14-16, 20-21] and Denmark.[18-19]  
 
The significant reduction in CNS visits may indicate that a large proportion of follow-up 
appointments in nurse-led DMARD monitoring clinics are made habitually and may not be 
clinically necessary, reflecting previous reports.[9] A parallel reduction in GP attendance is 
encouraging, as this indicates that patients were not redirecting their care, but felt better 
able to manage their arthritis at home themselves rather than seek help in primary care, 
possibly because they knew rapid access to the CNS was available, as suggested elsewhere 
in the literature.[42] Further cost-effectiveness analyses needs to be performed in order to 
understand how these reductions translate into cost savings.   
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The clinical care and safety of participants in the intervention group was of high priority. Of 
the 52 participants randomised to the intervention group two participants returned to usual 
care due to concerns about safety. Despite receiving the standardised training session and 
support from the research team, which included a CNS and rheumatologist, these patients 
were unable to accurately initiate care when their blood test results were either outside of 
the normal range or had changed significantly since their last blood test. Concerns regarding 
participant safety, specifically in relation to deterioration of disease status, have been 
reported elsewhere in the literature.[14-16] At the 2 year follow-up 12.5% of participants 
either withdrew or were withdrawn because of non-compliance with the safety monitoring 
procedures, which included 3-monthly questionnaires assessing clinical status.[14] In the 
study reported here the final blood test however, almost 90% of patients were safely 
initiating care from their CNS, with accuracy improving over time in response to the 
feedback given to patients at prior blood tests. This may indicate that any service 
implemented would need to have a pilot phase for each patient to ensure a high level of 
accuracy is achieved prior to independent self-monitoring. 
 
It is reassuring that an intervention that required patients to pay closer attention to their 
illness and reduced unnecessary healthcare visits did not have a detrimental impact on 
patients’ psychosocial well-being. Contrary to the expectations of some rheumatology 
healthcare professionals[43] increasing patient knowledge, understanding and exposure to 
blood test results whilst at the same time decreasing healthcare utilisation was not 
associated with increased levels of anxiety. In fact there was tentative evidence to suggest 
that participants in receipt of the new service experienced improving levels of anxiety 
McBain, H., Shipley, M., Olaleye, A., Moore, S. & Newman, S. (accepted). A patient-initiated DMARD self-
monitoring service for people with rheumatoid or psoriatic arthritis on methotrexate: a randomised controlled 
trial. Annals of Rheumatic Diseases. 
 
19 
compared to participants under control conditions, consistent with other trials of patient-
initiated services.[14-15]  
 
Increasing patients’ understanding of and exposure to blood test results, and the use of 
these as triggers to access care from the CNS was a unique addition to the service. This, in 
addition to the provision of pre-filled blood test forms may explain why participants in the 
intervention group attended for their blood tests more frequently than control group 
participants, as theorized elsewhere in the literature.[44] Although frequency of attendance 
for blood tests does not necessarily reflect recommended scheduling, this finding is in 
contrast to other patient-initiated services, which have reported that patients initiating their 
own care are less adherent to their blood monitoring schedules than those monitored by a 
rheumatologist.[18] 
 
Limitations of this trial relate to rates of refusal and study methodology. Data on the length 
of each telephone call was not available, an important factor when considering the capacity 
to take on such activities particularly as many rheumatology nurses are being asked to 
change their usual work pattern or take on extra work which nurses themselves have 
described as “increased activity without increased resources”.[45] The costs of delivering a 
telephone consultation is, however, the same per patient irrespective of time.[46] 
Additionally, data were not available on the number of telephone calls made by the control 
group to the nurse helpline. Nor was data collected in either groups on use of other services 
such as physiotherapy, occupational therapy or podiatry.    
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A third of eligible patients preferred to have regular scheduled appointments with their CNS 
face-to-face, which has been reported as a reason for refusal in other patient-initiated 
trials.[18-19, 47] The increased level of involvement and additional responsibility for self-
monitoring blood tests in this trial may explain the higher overall proportion of refusals in 
comparison to other trials.[47] Refusal to participate in trials that increase patient 
involvement in healthcare has been linked to a reluctance to disrupt services and 
relationships that are working well and are highly valued.[48] This may further account for 
the high rates of refusal found in the current trial, particularly as nurse-led services are 
associated with greater levels of satisfaction with care than consultant-led clinics.[49] In 
countries in which the role of the CNS in rheumatology is still in its infancy,[50-52] there is 
still much work to done to establish these services. In light of this study consideration may 
now be given to telephone as opposed to face-to-face follow-up.  
 
Methodologically, random allocation was undertaken prior to baseline assessment, which 
may mean that participants reported poorer psychosocial well-being than if they had been 
randomised after baseline assessment.[53] Lack of allocation concealment and blinding may 
have also biased the effects of the service.[54-55] Finally, the single centre status of the trial 
has reduced the external validity of the findings,[56] and may have led to larger intervention 
effects on both the continuous[57] and binary outcomes.[58] A larger multi-centre RCT 
would therefore be required in order to test our hypothesis more robustly. Finally, although 
this trial suggests equivalence between the intervention and control arm on psychosocial 
outcomes, this study was not designed to test equivalence and hence these conclusions 
should be treated with caution. 
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CONCLUSION 
This RCT demonstrated that a self-monitoring and patient-initiated service can lead to clear 
reductions in primary and secondary healthcare services, whilst at the same time 
maintaining patients’ clinical and psychosocial well-being in comparison to nurse-led 
DMARD monitoring clinics. Further work is needed in order to establish the cost-
effectiveness of the service. 
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Table S1. MLM analysis for laboratory tests (n=100) 
Test  Trial arm  Pre-trial  1 2 3 4 5 6   
Haemoglobin  Intervention  13.91(1.37)  14.01(1.37)  13.96(1.38)  13.88(1.33)  13.88(1.33)  13.95(1.34)  13.82(1.40)  Group*Time  
 Control  13.35(1.53)  13.29(1.53)  13.25(1.47)  13.23(1.47)  13.39(1.49)  13.54(1.55)  13.29(1.56)  F6,302.56 = 
0.75,  
p = 0.61 Effect size (99% CI)  0.49(0.00,0.98)  0.49(0.00,0.99)  0.46(-0.03,0.95)  0.34(-0.15,0.84)  0.28(-0.22,0.78)  0.36(-0.15,0.86)  
WBC  Intervention  6.79(1.77)  6.76(1.77)  6.93(1.78)  7.11(1.73)  6.73(1.74)  6.99(1.75)  6.80(1.85)  F2,290.87 = 
0.39,  
p = 0.89 
 Control  6.65(1.96)  6.88(1.98)  7.00(1.90)  6.97(1.92)  7.00(1.95)  7.01(2.04)  6.86(2.05)  
Effect size (99% CI)  0.06(-0.57,0.69)  0.04(-0.60,0.68)  0.08(-0.57,0.72)  0.14(-0.50,0.79)  0.01(-0.64,0.67)  0.03(-0.63,0.69)  
Neutrophils  Intervention  4.28(1.53)  3.96(1.53)  4.04(1.55)  4.26(1.50)  3.96(1.50)  4.15(1.54)  3.93(1.62)  F6,288.13 = 
1.33,  
p = 0.25 
 Control  3.84(1.70)  4.23(1.71)  4.20(1.65)  4.30(1.66)  4.13(1.70)  4.22(1.77)  4.16(1.78)  
Effect size (99% CI)  0.16(-0.38,0.71)  0.10(-0.45,0.66)  0.02(-0.53,0.58)  0.11(-0.46,0.67)  0.04(-0.53,0.61)  0.13(-0.44,0.71)  
Platelets  Intervention  241.27(57.39)  238.27(57.39)  239.51(57.66)  240.82(55.59)  242.74(55.76)  245.19(56.32)  239.34(58.87)  
F6,299.34 = 
1.00,  
p = 0.43 
 Control  273.81(63.86)  277.70(64.06)  279.82(61.60)  278.44(61.79)  270.92(62.39)  273.21(62.05)  264.31(65.28)  
Effect size (99% CI)  0.64(-19.89,21.18)  0.67(-19.96,21.30)  0.64(-20.06,21.34)  0.47(-20.29,21.24)  0.46(-20.57,21.43)  
0.40(-
20.66,21.46)  
ALP  Intervention  73.13(20.60)  75.10(20.60)  72.71(20.71)  72.80(19.93)  70.87(19.99)  73.14(20.08)  73.20(20.97)  F6,297.91 = 
1.19,  
p = 0.31 
 Control  70.81(22.92)  72.83(22.98)  73.20(22.10)  73.03(22.15)  74.46(22.44)  75.68(23.36)  74.56(23.38)  
Effect size (99% CI)  0.10(-7.27,7.47)  0.02(-7.39,7.43)  0.01(-7.41,7.43)  0.17(-7.27,7.61)  0.12(-7.36,7.59)  0.06(-7.44,7.56)  
ALT  Intervention  28.88(16.51)  29.08(16.51)  31.75(16.70)  32.27(16.11)  30.10(16.28)  31.59(16.40)  31.59(17.21)  F6,209.46 = 
1.58,  
p = 0.15 
 Control  26.93(18.37)  26.02(18.70)  28.34(17.77)  25.05(17.96)  29.85(18.51)  26.93(19.37)  28.70(19.22)  
Effect size (99% CI)  0.17(-5.73,6.08)  0.20(-5.78,6.17)  0.42(-5.58,6.42)  0.01(-6.05,6.08)  0.26(-5.85,6.37)  0.16(-6.00,6.31)  
ESR  Intervention  13.54(12.63)  13.15(12.69)  13.09(12.77)  12.21(12.60)  12.63(12.49)  13.04(12.63)  12.17(13.23)  F6,300.96 = 
0.35,  
p = 0.91 
 Control  13.55(14.06)  15.69(14.51)  13.88(13.69)  12.68(13.96)  14.17(14.19)  13.36(14.58)  14.36(14.80)  
Effect size (99% CI)  0.19(-4.35,4.72)  0.06(-4.51,4.63)  0.04(-4.66,4.73)  0.11(-4.53,4.76)  0.02(-4.68,4.73)  0.16(-4.58,4.89)  
CRP  Intervention  5.07(8.34)  4.60(8.41)  4.87(8.62)  5.89(8.23)  4.73(8.46)  4.52(8.55)  5.23(8.91)  F6,279.19 = 
0.53,  
p = 0.78 
 Control  4.26(9.28)  5.89(9.47)  6.96(9.11)  7.50(9.21)  5.80(9.65)  4.23(9.96)  7.17(9.96)  
Effect size (99% CI)  0.14(-2.86,3.15)  0.23(-2.85,3.32)  0.18(-2.88,3.25)  0.12(-3.03,3.27)  0.03(-3.15,3.22)  0.21(-2.98,3.39  
 
 
